查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1422854

2024-2032 年按类型、配销通路、应用和地区分類的免疫检查点抑制剂市场报告

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

2023年全球免疫检查点抑制剂市场规模达431亿美元。展望未来， IMARC Group预计到2032年市场规模将达到1,572亿美元，2024-2032年复合年增长率（CAGR）为15.01%。各种癌症盛行率的上升、呼吸系统疾病发生率的增加以及对个人化药物的日益偏好是推动市场发展的一些关键因素。

免疫检查点抑制剂是一种透过抑制免疫系统细胞（例如 T 细胞和癌细胞）产生的特定蛋白质来治疗癌症的药物。它们可以单独使用，也可以与其他癌症治疗方法（例如化疗和放射治疗）结合使用，以增强治疗效果。它们透过减少疾病症状并延长癌症患者的生存期来帮助提高癌症患者的生活品质。免疫检查点抑制剂针对免疫系统中的特定途径，从而实现更有针对性的癌症治疗方法。与传统化疗相比，这些抑制剂的毒性较低，副作用较少，患者的耐受性较好。目前，越来越多地使用新一代定序技术来识别癌细胞中的特定基因突变，从而刺激了全球对免疫检查点抑制剂的需求。

免疫检查点抑制剂市场趋势：

黑色素瘤、肝癌、肾癌和胃癌等各种癌症在个体中的盛行率激增，是推动全球免疫检查点抑制剂需求的主要因素之一。此外，人口老化的加剧，更容易罹患这种严重的癌症，以及肥胖症盛行率的上升，有利于市场的成长。此外，由于酒精饮料和烟草製品消费量的增加，呼吸系统疾病的发生率也有所增加。再加上由于不健康的饮食习惯和久坐的生活方式而引起的与体重相关的健康问题日益增多，正在对市场产生积极影响。除此之外，各种遗传和生活方式疾病的激增以及个人和医疗保健专业人员对癌症早期诊断和治疗的好处的认识不断提高，正在推动市场的成长。此外，製药公司临床试验数量的不断增加以及对个人化药物和新一代药物和製剂的日益青睐正在推动市场的成长。除此之外，领导企业越来越注重策略合作和新产品开发，以扩大其产品组合併获得竞争优势，这为市场创造了积极的前景。此外，医疗基础设施和诊断技术的显着改善预计将加强市场的成长。

本报告回答的关键问题

  • 全球免疫检查点抑制剂市场有多大？
  • 2024-2032年全球免疫检查点抑制剂市场的预期成长率是多少？
  • 推动全球免疫检查点抑制剂市场的关键因素是什么？
  • COVID-19对全球免疫检查点抑制剂市场有何影响？
  • 全球免疫检查点抑制剂市场按类型划分是怎样的？
  • 基于配销通路的全球免疫检查点抑制剂市场的细分情况如何？
  • 基于应用的全球免疫检查点抑制剂市场的细分如何？
  • 全球免疫检查点抑制剂市场的重点区域有哪些？
  • 全球免疫检查点抑制剂市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球免疫检查点抑制剂市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • CTLA-4抑制剂
    • 市场走向
    • 市场预测
  • PD-1抑制剂
    • 市场走向
    • 市场预测
  • PD-L1抑制剂
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按应用

  • 肺癌
    • 市场走向
    • 市场预测
  • 膀胱癌
    • 市场走向
    • 市场预测
  • 黑色素瘤
    • 市场走向
    • 市场预测
  • 大肠直肠癌
    • 市场走向
    • 市场预测
  • 霍奇金淋巴瘤
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • GSK plc
    • Merck & Co. Inc.
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Seagen Inc.
Product Code: SR112024A7221

Abstract

The global immune checkpoint inhibitors market size reached US$ 43.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 157.2 Billion by 2032, exhibiting a growth rate (CAGR) of 15.01% during 2024-2032. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, distribution channel, and application.

Type Insights:

CTLA-4 Inhibitor

PD-1 Inhibitor

PD-L1 Inhibitor

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Application Insights:

Lung Cancer

Bladder Cancer

Melanoma

Colorectal Cancer

Hodgkin Lymphoma

Others

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.

Key Questions Answered in This Report

  • 1. How big is the global immune checkpoint inhibitors market?
  • 2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2024-2032?
  • 3. What are the key factors driving the global immune checkpoint inhibitors market?
  • 4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
  • 5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
  • 6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
  • 7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
  • 8. What are the key regions in the global immune checkpoint inhibitors market?
  • 9. Who are the key players/companies in the global immune checkpoint inhibitors market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immune Checkpoint Inhibitors Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 CTLA-4 Inhibitor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 PD-1 Inhibitor
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 PD-L1 Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lung Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bladder Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Colorectal Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hodgkin Lymphoma
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Ono Pharmaceutical Co. Ltd.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Regeneron Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Seagen Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
  • Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
  • Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
  • Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players